Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

Nature Medicine

Volumn 21, Issue 8, 2015, Pages 922-926

  Wilson, Wyndham H ^a   Young, Ryan M ^a   Schmitz, Roland ^a   Yang, Yandan ^a   Pittaluga, Stefania ^a   Wright, George ^a   Lih, Chih Jian ^b   Williams, P Mickey ^b   Shaffer, Arthur L ^a   Gerecitano, John ^c,d   De Vos, Sven ^e   Goy, Andre ^f   Kenkre, Vaishalee P ^g   Barr, Paul M ^h   Blum, Kristie A ⁱ   Shustov, Andrei ^j   Advani, Ranjana ^k   Fowler, Nathan H ^l   Vose, Julie M ^m   Elstrom, Rebecca L ⁿ   Habermann, Thomas M ^o   Barrientos, Jacqueline C ^p   McGreivy, Jesse ^q   Fardis, Maria ^q   Chang, Betty Y ^q   Clow, Fong ^q   Munneke, Brian ^q   Moussa, Davina ^q   Beaupre, Darrin M ^q   Staudt, Louis M ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF WISCONSIN MADISON   (United States)

^h UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

ⁱ OHIO STATE UNIVERSITY   (United States)

^j UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^k STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^m UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

ⁿ GENENTECH INC   (United States)

^o MAYO CLINIC   (United States)

^p DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^q PHARMACYCLICS INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; IBRUTINIB; CD79 ANTIGEN; CD79A PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR; MYD88 PROTEIN, HUMAN; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER PATIENT; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG TOLERABILITY; FOLLOW UP; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FREQUENCY; GERMINAL CENTER; HUMAN; IN VITRO STUDY; LARGE CELL LYMPHOMA; MALE; OVERALL SURVIVAL; PATHOGENESIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TREATMENT DURATION; CLINICAL TRIAL; DRUG EFFECTS; FEMALE; GENETICS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; MOLECULAR GENETICS; MORTALITY; MUTATION; NUCLEOTIDE SEQUENCE; PHYSIOLOGY;

ADULT; AGED; ANTIGENS, CD79; BASE SEQUENCE; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIMIDINES; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION;

EID: 84938994998     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3884     Document Type: Article

References (18)

1. Shaffer, A.L. III, Young, R.M. & Staudt, L.M. Pathogenesis of human B cell lymphomas. Annu. Rev. Immunol. 30, 565-610 (2012).
2. Lenz, G. et al. Stromal gene signatures in large-B-cell lymphomas. N. Engl. J. Med. 359, 2313-2323 (2008).
3. Davis, R.E., Brown, K.D., Siebenlist, U. & Staudt, L.M. Constitutive nuclear factor kappa B activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 194, 1861-1874 (2001).
4. Davis, R.E. et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463, 88-92 (2010).
5. Ngo, V.N. et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 470, 115-119 (2011).
6. Lenz, G. et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 319, 1676-1679 (2008).
7. Compagno, M. et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 459, 717-721 (2009).
8. Yang, Y. et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 21, 723-737 (2012).
9. Sehn, L.H. et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109, 1857-1861 (2007).
10. Loiarro, M. et al. Peptide-mediated interference of TIR domain dimerization in MyD88 inhibits interleukin-1-dependent activation of NF-κB. J. Biol. Chem. 280, 15809-15814 (2005).
11. Young, R.M. & Staudt, L.M. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat. Rev. Drug Discov. 12, 229-243 (2013).
12. Schmitz, R. et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 490, 116-120 (2012).
13. Byrd, J.C. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369, 32-42 (2013).
14. Wang, M.L. et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 369, 507-516 (2013).
15. Quesada, V. et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat. Genet. 44, 47-52 (2012).
16. Be, S. et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc. Natl. Acad. Sci. USA 110, 18250-18255 (2013).
17. Wang, L. et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N. Engl. J. Med. 365, 2497-2506 (2011).
18. Cheson, B.D. et al. Revised response criteria for malignant lymphoma. J. Clin. Oncol. 25, 579-586 (2007).